Unlocking novel targets to redefine what's possible for people with hard-to-treat cancers
Too many cancers remain defined by what we don't understand—and what we can’t yet target.
At IDEAYA, we're uncovering the hidden vulnerabilities behind these diseases and developing innovative targeted approaches to treat them. Our ambition is clear: deliver transformative therapies to patients who need them most.
IDEAYA R&D STRATEGY
Targeting cancer’s key drivers
Established R&D engine built to deliver first-in-class targeted therapies and rational combinations to treat molecularly defined cancers. Pipeline priorities:
PKC Inhibition in uveal melanoma (UM)
Target the main oncogenic driver of uveal melanoma
ADC+DDR Combos
Improve efficacy and durability of TOP1 ADCs
MTAP Pathway
Exploit a metabolic vulnerability in MTAP-deleted cancers
KAT6/7 Inhibition
Simultaneously target key epigenetic drivers of cancer
IDEAYA is advancing a deep pipeline of clinical-stage precision medicines for multiple potential solid tumor indications.
OUR LEAD PRECISION MEDICINE
Darovasertib has the potential to be the first targeted therapy for all stages of uveal melanoma (UM)
Our lead investigational candidate, darovasertib, is currently in late-stage and registrational trials across all stages of UM, with anticipated regulatory submission for metastatic uveal melanoma (mUM) in the second half of 2026.
A rare and aggressive cancer, UM has very limited treatment options and severe consequences for patients at all stages of disease:1-3
Majority of primary UM patients lose their eye or face permanent vision loss from radiation therapy3
Approximately 50% of patients with UM will progress to metastatic disease4
Even with available treatments, mUM has a poor prognosis and historically, most patients live less than 1 year5,6
No current treatments target PKC, the key oncogenic pathway in >90% of UM.6,7
Discover IDEAYA
PKC = Protein kinase C, UM = uveal melanoma, mUM = metastatic uveal melanoma